The comparative toxicity and therapeutic efficacy of adriamycin and the adriamycin-DNA complex in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.
Tissue analyses and tumour regression studies using the oncolytic antibiotic, adriamycin (14-hydroxydaunomycin), and its DNA complex at adriamycin dosages of 5 mg/kg and 10 mg/kg were made on C3H mice with transplanted mammary adenocarcinoma. Chemical analysis indicated a significantly lower (P < 0.05) uptake of adriamycin into cardiac tissue for the adriamycin-DNA complex. Tumour regression was comparable for both the complex and free adriamycin. Results suggest an advantageous role for the adriamycin DNA complex in the chemotherapy of metastatic breast carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism*; D000818:Animals; D004247:DNA / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity*; D018736:DNA Adducts; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity*; D005260:Female; D007274:Injections, Intraperitoneal; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D051379:Mice; D008809:Mice, Inbred C3H; D009206:Myocardium / Q000378:metabolism; D009368:Neoplasm Transplantation; D013810:Therapeutic Equivalency; D014018:Tissue Distribution
D018736:DNA Adducts; C031902:doxorubicin-DNA; D004317:Doxorubicin; D004247:DNA